John Burn-Murdoch

Whereas presumably what we're saying is if you detect them at that earlier stage, there is no trade-off.

The treatments there are not invasive.

I mean, you've been in this space for decades.

Would this be the most dramatic advanced breakthrough that you've seen?

Remarkable.

Well, let's hope we do get there in that time frame.

So thank you to Christopher for that question.

One from Sam.

What impact will the Trump administration have on the advance of medical science and what should the UK, and perhaps we could extend that to Europe, be doing in response?

Yeah, and I should just add there as well the comments you made about the Trump administration.

Of course, again, they're not in the room with us.

RFK is not here and they may have other things to say.

But there is a follow-up question on a related point, which comes in from Patrick Leary, who asks about the role of wealthy supporters of Trump and their prominence in the medical business.

There's a name here that you'll be familiar with.

You formerly were at the Ellison Institute, run by US tech giant Larry Ellison, who's doing a lot of interesting work in healthcare.

Are there risks when politics and medical research seem to develop this close reliance?

Right.

But I guess the broader question maybe is that when you have people like Ellison, who has a close relationship with Trump, you're exposing yourself to vulnerabilities.

Those kind of decisions, those whiplashes from one to the other are more likely when there's that proximity between key figures in the two.

We now have another question from Pritesh who asks, what are the short, medium and long-term scaling challenges here and how can the NHS itself mitigate them and get the best outcomes from this space?